The engineers of human souls & academia
Identifieur interne : 000996 ( Istex/Corpus ); précédent : 000995; suivant : 000997The engineers of human souls & academia
Auteurs : David HealySource :
- Epidemiologia e Psichiatria Sociale [ 1121-189X ] ; 2007-09.
Abstract
Aims – There has been recent concern about interactions between academia and the pharmaceutical industry. This article seeks to explore the basis for the current sense of crisis. Methods – The approach taken is a historical one, outlining the origins of the crisis. Results – The analysis outlines the roles that brands, patents, and the control of the scientific literature play in the current marketing of psychotropic drugs, and describes the processes of guideline capture and brand fascism. Conclusions – The analysis makes it difficult to see current interactions between industry and academia as anything but bad for academia. One option that might restore some balance would be to restrict scientific meetings and journals to communications that made all relevant scientific data available, excluding exercises that restrict access to data. Declaration of Interest: In recent years I have had consultancies with, or been a chairman or speaker at symposia for, or received support to attend meetings from Astra-Zeneca, and Lundbeck. I have been expert witness for the plaintiff in the past decade in 15 legal actions involving antidepressants and on patent case, and have been consulted on a much greater number of attempted suicide, suicide, and suicide-homicide cases linked to treatment, in which I have offered the view that the treatment was not involved or have declined to give a view.
Url:
DOI: 10.1017/S1121189X0000230X
Links to Exploration step
ISTEX:E9BF9DC0746E22F7668269B6A6EED6928D58131ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>The engineers of human souls & academia</title><author><name sortKey="Healy, David" sort="Healy, David" uniqKey="Healy D" first="David" last="Healy">David Healy</name><affiliation><mods:affiliation>E-mail: Healy_Hergest@compuserve.com</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E9BF9DC0746E22F7668269B6A6EED6928D58131E</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1017/S1121189X0000230X</idno><idno type="url">https://api.istex.fr/ark:/67375/6GQ-R442T4MV-M/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000996</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000996</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">The engineers of human souls & academia</title><author><name sortKey="Healy, David" sort="Healy, David" uniqKey="Healy D" first="David" last="Healy">David Healy</name><affiliation><mods:affiliation>E-mail: Healy_Hergest@compuserve.com</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Epidemiologia e Psichiatria Sociale</title><title level="j" type="abbrev">Epidemiol Psichiatr Soc</title><idno type="ISSN">1121-189X</idno><idno type="eISSN">2038-1816</idno><imprint><publisher>Cambridge University Press</publisher><pubPlace>Cambridge, UK</pubPlace><date type="published" when="2007-09">2007-09</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="205">205</biblScope><biblScope unit="page" to="211">211</biblScope></imprint><idno type="ISSN">1121-189X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1121-189X</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Aims – There has been recent concern about interactions between academia and the pharmaceutical industry. This article seeks to explore the basis for the current sense of crisis. Methods – The approach taken is a historical one, outlining the origins of the crisis. Results – The analysis outlines the roles that brands, patents, and the control of the scientific literature play in the current marketing of psychotropic drugs, and describes the processes of guideline capture and brand fascism. Conclusions – The analysis makes it difficult to see current interactions between industry and academia as anything but bad for academia. One option that might restore some balance would be to restrict scientific meetings and journals to communications that made all relevant scientific data available, excluding exercises that restrict access to data. Declaration of Interest: In recent years I have had consultancies with, or been a chairman or speaker at symposia for, or received support to attend meetings from Astra-Zeneca, and Lundbeck. I have been expert witness for the plaintiff in the past decade in 15 legal actions involving antidepressants and on patent case, and have been consulted on a much greater number of attempted suicide, suicide, and suicide-homicide cases linked to treatment, in which I have offered the view that the treatment was not involved or have declined to give a view.</div></front></TEI><istex><corpusName>cambridge</corpusName><author><json:item><name>David Healy</name><affiliations><json:string>E-mail: Healy_Hergest@compuserve.com</json:string></affiliations></json:item></author><articleId><json:string>00230</json:string></articleId><arkIstex>ark:/67375/6GQ-R442T4MV-M</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>Aims – There has been recent concern about interactions between academia and the pharmaceutical industry. This article seeks to explore the basis for the current sense of crisis. Methods – The approach taken is a historical one, outlining the origins of the crisis. Results – The analysis outlines the roles that brands, patents, and the control of the scientific literature play in the current marketing of psychotropic drugs, and describes the processes of guideline capture and brand fascism. Conclusions – The analysis makes it difficult to see current interactions between industry and academia as anything but bad for academia. One option that might restore some balance would be to restrict scientific meetings and journals to communications that made all relevant scientific data available, excluding exercises that restrict access to data. Declaration of Interest: In recent years I have had consultancies with, or been a chairman or speaker at symposia for, or received support to attend meetings from Astra-Zeneca, and Lundbeck. I have been expert witness for the plaintiff in the past decade in 15 legal actions involving antidepressants and on patent case, and have been consulted on a much greater number of attempted suicide, suicide, and suicide-homicide cases linked to treatment, in which I have offered the view that the treatment was not involved or have declined to give a view.</abstract><qualityIndicators><score>9.524</score><pdfWordCount>4872</pdfWordCount><pdfCharCount>29616</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>7</pdfPageCount><pdfPageSize>576 x 777.6 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>221</abstractWordCount><abstractCharCount>1399</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>The engineers of human souls & academia</title><pii><json:string>S1121189X0000230X</json:string></pii><genre><json:string>research-article</json:string></genre><host><title>Epidemiologia e Psichiatria Sociale</title><language><json:string>unknown</json:string></language><issn><json:string>1121-189X</json:string></issn><eissn><json:string>2038-1816</json:string></eissn><publisherId><json:string>EPS</json:string></publisherId><volume>16</volume><issue>3</issue><pages><first>205</first><last>211</last><total>7</total></pages><genre><json:string>journal</json:string></genre></host><ark><json:string>ark:/67375/6GQ-R442T4MV-M</json:string></ark><categories><inist><json:string>1 - sciences humaines et sociales</json:string></inist></categories><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1017/S1121189X0000230X</json:string></doi><id>E9BF9DC0746E22F7668269B6A6EED6928D58131E</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6GQ-R442T4MV-M/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6GQ-R442T4MV-M/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6GQ-R442T4MV-M/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">The engineers of human souls & academia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Cambridge University Press</publisher><pubPlace>Cambridge, UK</pubPlace><availability><licence><p>Copyright © Cambridge University Press 2007</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-G3RCRD03-V">cambridge</p></availability><date>2007</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">The engineers of human souls & academia</title><author xml:id="author-0000"><persName><forename type="first">David</forename><surname>Healy</surname></persName><email>Healy_Hergest@compuserve.com</email></author><idno type="istex">E9BF9DC0746E22F7668269B6A6EED6928D58131E</idno><idno type="ark">ark:/67375/6GQ-R442T4MV-M</idno><idno type="DOI">10.1017/S1121189X0000230X</idno><idno type="PII">S1121189X0000230X</idno><idno type="article-id">00230</idno></analytic><monogr><title level="j">Epidemiologia e Psichiatria Sociale</title><title level="j" type="abbrev">Epidemiol Psichiatr Soc</title><idno type="pISSN">1121-189X</idno><idno type="eISSN">2038-1816</idno><idno type="publisher-id">EPS</idno><imprint><publisher>Cambridge University Press</publisher><pubPlace>Cambridge, UK</pubPlace><date type="published" when="2007-09"></date><biblScope unit="volume">16</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="205">205</biblScope><biblScope unit="page" to="211">211</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract style="normal"><p>Aims – There has been recent concern about interactions between academia and the pharmaceutical industry. This article seeks to explore the basis for the current sense of crisis. Methods – The approach taken is a historical one, outlining the origins of the crisis. Results – The analysis outlines the roles that brands, patents, and the control of the scientific literature play in the current marketing of psychotropic drugs, and describes the processes of guideline capture and brand fascism. Conclusions – The analysis makes it difficult to see current interactions between industry and academia as anything but bad for academia. One option that might restore some balance would be to restrict scientific meetings and journals to communications that made all relevant scientific data available, excluding exercises that restrict access to data. Declaration of Interest: In recent years I have had consultancies with, or been a chairman or speaker at symposia for, or received support to attend meetings from Astra-Zeneca, and Lundbeck. I have been expert witness for the plaintiff in the past decade in 15 legal actions involving antidepressants and on patent case, and have been consulted on a much greater number of attempted suicide, suicide, and suicide-homicide cases linked to treatment, in which I have offered the view that the treatment was not involved or have declined to give a view.</p></abstract></profileDesc><revisionDesc><change when="2007-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6GQ-R442T4MV-M/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus cambridge not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="US-ASCII"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Publishing DTD v2.2 20060430//EN" URI="journalpublishing.dtd" name="istex:docType"></istex:docType><istex:document><article dtd-version="2.2" article-type="research-article"><front><journal-meta><journal-id journal-id-type="publisher-id">EPS</journal-id><journal-title>Epidemiologia e Psichiatria Sociale</journal-title><abbrev-journal-title>Epidemiol Psichiatr Soc</abbrev-journal-title><issn pub-type="ppub">1121-189X</issn><issn pub-type="epub">2038-1816</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1017/S1121189X0000230X</article-id><article-id pub-id-type="pii">S1121189X0000230X</article-id><article-id pub-id-type="publisher-id">00230</article-id><title-group><article-title>The engineers of human souls & academia</article-title><alt-title alt-title-type="left-running">D. Healy</alt-title><alt-title alt-title-type="right-running">The engineers of human souls & academia</alt-title></title-group><contrib-group><contrib><name><surname>Healy</surname><given-names>David</given-names></name><xref ref-type="corresp" rid="cor1"></xref></contrib></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Professor D. Healy, <institution>Cardiff University</institution>, <addr-line>Hergest Unit</addr-line>, <addr-line>Wales LL57 2PW</addr-line> (<country>United Kingdom</country>). Fax: <fax>+44-1248-371397</fax> E-mail: <email xlink:href="Healy_Hergest@compuserve.com">Healy_Hergest@compuserve.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>09</month><year>2007</year></pub-date><volume>16</volume><issue>3</issue><fpage seq="8">205</fpage><lpage>211</lpage><permissions><copyright-statement>Copyright © Cambridge University Press 2007</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Cambridge University Press</copyright-holder></permissions><abstract abstract-type="normal"><title>Summary</title><p><bold>Aims</bold> – There has been recent concern about interactions between academia and the pharmaceutical industry. This article seeks to explore the basis for the current sense of crisis. <bold>Methods</bold> – The approach taken is a historical one, outlining the origins of the crisis. <bold>Results</bold> – The analysis outlines the roles that brands, patents, and the control of the scientific literature play in the current marketing of psychotropic drugs, and describes the processes of guideline capture and brand fascism. <bold>Conclusions</bold> – The analysis makes it difficult to see current interactions between industry and academia as anything but bad for academia. One option that might restore some balance would be to restrict scientific meetings and journals to communications that made all relevant scientific data available, excluding exercises that restrict access to data.</p><p><bold>Declaration of Interest</bold>: In recent years I have had consultancies with, or been a chairman or speaker at symposia for, or received support to attend meetings from Astra-Zeneca, and Lundbeck. I have been expert witness for the plaintiff in the past decade in 15 legal actions involving antidepressants and on patent case, and have been consulted on a much greater number of attempted suicide, suicide, and suicide-homicide cases linked to treatment, in which I have offered the view that the treatment was not involved or have declined to give a view.</p></abstract><counts><page-count count="7"></page-count></counts><custom-meta-wrap><custom-meta><meta-name>pdf</meta-name><meta-value>S1121189X0000230Xa.pdf</meta-value></custom-meta><custom-meta><meta-name>dispart</meta-name><meta-value>Special Articles</meta-value></custom-meta></custom-meta-wrap></article-meta></front><back><ref-list><title>REFERENCES</title><ref><citation id="ref001" citation-type="book"><name><surname>Angell</surname><given-names>M.</given-names></name> (<year>2005</year>). <source>The Truth about the Drug Companies. How They Deceive Us and What to Do About It</source>. <publisher-name>Random House</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation></ref><ref><citation id="ref002" citation-type="book"><name><surname>Applbaum</surname><given-names>K.</given-names></name> (<year>2004</year>). <source>The Marketing Era</source>. <publisher-name>Routledge</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation></ref><ref><citation id="ref003" citation-type="journal"><name><surname>Ban</surname><given-names>T.A.</given-names></name> (<year>1987</year>). <article-title>Prolegomenon to the clinical prerequisite. Psychopharmacology and the classification of mental disorders</article-title>. <source>Progress in Neuro-Psychopharmacology & Biological Psychiatry</source> <volume>11</volume>,<fpage>527</fpage>–<lpage>580</lpage>.</citation></ref><ref><citation id="ref004" citation-type="journal"><name><surname>Ban</surname><given-names>T.A.</given-names></name> (<year>2006</year>). <article-title>Academic psychiatry and the pharmaceutical industry</article-title>. <source>Progress in Neuro-Psychopharmacology & Biological Psychiatry</source> <volume>30</volume>,<fpage>429</fpage>–<lpage>441</lpage>.</citation></ref><ref><citation id="ref005" citation-type="other"><name><surname>Blumsohn</surname><given-names>A</given-names></name> (<year>2006</year>a). Scientific Misconduct Blog. Retrieved June 4, 2007, from http://scientific-misconduct.blogspot.com/</citation></ref><ref><citation id="ref006" citation-type="journal"><name><surname>Blumsohn</surname><given-names>A.</given-names></name> (<year>2006</year>b). <article-title>Authorship, ghost-science, access to data and control of the pharmaceutical scientific literature: who stands behind the word?</article-title> <source>Professional Ethics Report</source> <volume>19</volume>(<issue>3</issue>). Retrieved June 4, 2007, from http://www.aaas.org/spp/sfrl/per/per46.pdf</citation></ref><ref><citation id="ref007" citation-type="journal"><name><surname>Colton</surname><given-names>C.W.</given-names></name> & <name><surname>Manderscheid</surname><given-names>R.W.</given-names></name> (<year>2006</year>). <article-title>Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states</article-title>. <source>Preventive Chronic Disease</source> <volume>3</volume>(<issue>2</issue>). Retrieved June 4, 2007, from http://www.cdc. gov/pcd/issues/2006/apr/05_0180.htm.</citation></ref><ref><citation id="ref008" citation-type="other"><name><surname>Davies</surname><given-names>H</given-names></name> (<year>2001</year>). The role of the private sector in protecting human subjects. Institute of Medicine. Retrieved June 4, 2007, from http:// www.acrohealth.org/testimony.php?yr=2001</citation></ref><ref><citation id="ref009" citation-type="other"><name><surname>Delay</surname><given-names>J.</given-names></name>, <name><surname>Deniker</surname><given-names>P.</given-names></name> & <name><surname>Ropert</surname><given-names>R</given-names></name> (<year>1955</year>). Etude de 300 dossiers de maladies psychotiques traits par la chlorpromazine en service fermé depuis 1952. <italic>Encephalè</italic> <fpage>528</fpage>–<lpage>535</lpage>.</citation></ref><ref><citation id="ref010" citation-type="journal"><name><surname>Fava</surname><given-names>G.</given-names></name> (<year>2007</year>). <article-title>Financial conflicts of interest in psychiatry</article-title>. <source>World Psychiatric Association Journal</source> <volume>6</volume>(<issue>1</issue>), <fpage>19</fpage>–<lpage>24</lpage>.</citation></ref><ref><citation id="ref011" citation-type="journal"><name><surname>Fish</surname><given-names>F</given-names></name> (<year>1964</year>). <article-title>The influence of the tranquilizers on the Leonhard schizophrenic syndromes</article-title>. <source>Encephale</source> <volume>53</volume>, <fpage>245</fpage>–<lpage>249</lpage>.</citation></ref><ref><citation id="ref012" citation-type="journal"><name><surname>Fugh-Berman</surname><given-names>A.</given-names></name> (<year>2006</year>). <article-title>Doctors must not be lapdogs to drug firms</article-title>. <source>British Medical Journal</source> <volume>333</volume>, <fpage>1027</fpage>.</citation></ref><ref><citation id="ref013" citation-type="journal"><name><surname>Getz</surname><given-names>K.</given-names></name> & <name><surname>De Bruin</surname><given-names>A.</given-names></name> (<year>2000</year>). <article-title>Breaking the development speed barrier</article-title>. <source>Drug Information Journal</source> <volume>34</volume>, <fpage>725</fpage>–<lpage>736</lpage>.</citation></ref><ref><citation id="ref014" citation-type="book"><name><surname>Healy</surname><given-names>D.</given-names></name> (<year>1997</year>). <source>The Antidepressant Era</source>. <publisher-name>Harvard University Press</publisher-name>: <publisher-loc>Cambridge Mass</publisher-loc>.</citation></ref><ref><citation id="ref015" citation-type="book"><name><surname>Healy</surname><given-names>D.</given-names></name> (<year>2004</year>). <source>Let Them Eat Prozac</source>. <publisher-name>New York University Press</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation></ref><ref><citation id="ref016" citation-type="other"><name><surname>Healy</surname><given-names>D.</given-names></name> (<year>2006</year>a). The latest mania. Selling bipolar disorder. <italic>PloS Medicine</italic>. Retrieved June 4, 2007, from http://dx.doi.org/10.1371/ journal.pmed.0030185</citation></ref><ref><citation id="ref017" citation-type="journal"><name><surname>Healy</surname><given-names>D.</given-names></name> (<year>2006</year>b). <article-title>Manufacturing Consensus</article-title>. <source>Culture, Medicine and Psychiatry</source> <volume>30</volume>, <fpage>135</fpage>–<lpage>156</lpage>.</citation></ref><ref><citation id="ref018" citation-type="other"><name><surname>Healy</surname><given-names>D</given-names></name> (<year>2006</year>c). Let them eat Prozac. Retrieved June 4, 2007, from http://www.healyprozac.com/AcademicStalking/default.htm</citation></ref><ref><citation id="ref019" citation-type="other"><name><surname>Healy</surname><given-names>D.</given-names></name> (submitted for publication). Trussed in Evidence? Ambiguities at the interface of Clinical Evidence and Clinical Practice. <italic>Transcultural Psychiatry</italic>.</citation></ref><ref><citation id="ref020" citation-type="journal"><name><surname>Healy</surname><given-names>D.</given-names></name> & <name><surname>Cattell</surname><given-names>D.</given-names></name> (<year>2003</year>). <article-title>The Interface between authorship, industry and science in the domain of therapeutics</article-title>. <source>British Journal of Psychiatry</source> <volume>182</volume>, <fpage>22</fpage>–<lpage>27</lpage>.</citation></ref><ref><citation id="ref021" citation-type="journal"><name><surname>Healy</surname><given-names>D.</given-names></name>, <name><surname>Savage</surname><given-names>M.</given-names></name>, <name><surname>Michael</surname><given-names>P.</given-names></name>, <name><surname>Harris</surname><given-names>M.</given-names></name>, <name><surname>Hirst</surname><given-names>D.</given-names></name>, <name><surname>Carter</surname><given-names>M.</given-names></name>, <name><surname>Cattell</surname><given-names>D.</given-names></name>, <name><surname>McMonagle</surname><given-names>T.</given-names></name>, <name><surname>Sohler</surname><given-names>N.</given-names></name> & <name><surname>Susser</surname><given-names>E.</given-names></name> (<year>2001</year>). <article-title>Psychiatric bed utilisation: 1896 and 1996 compared</article-title>. <source>Psychological Medicine</source> <volume>31</volume>, <fpage>779</fpage>–<lpage>790</lpage>.</citation></ref><ref><citation id="ref022" citation-type="journal"><name><surname>Healy</surname><given-names>D.</given-names></name>, <name><surname>Harris</surname><given-names>M.</given-names></name>, <name><surname>Cattell</surname><given-names>D.</given-names></name>, <name><surname>Michael</surname><given-names>P.</given-names></name>, <name><surname>Chalasanni</surname><given-names>P.</given-names></name> & <name><surname>Hirst</surname><given-names>D.</given-names></name> (<year>2005</year>). <article-title>Service utilisation in 1896 and 1996: Morbidity and mortality data from North Wales</article-title>. <source>History of Psychiatry</source> <volume>16</volume>, <fpage>27</fpage>–<lpage>41</lpage>.</citation></ref><ref><citation id="ref023" citation-type="journal"><name><surname>Healy</surname><given-names>D.</given-names></name>, <name><surname>Harris</surname><given-names>M.</given-names></name>, <name><surname>Tranter</surname><given-names>R.</given-names></name>, <name><surname>Gutting</surname><given-names>P.</given-names></name>, <name><surname>Austin</surname><given-names>R.</given-names></name>, <name><surname>Jones-Edwards</surname><given-names>G.</given-names></name> & <name><surname>Roberts</surname><given-names>A.P.</given-names></name> (<year>2006</year>). <article-title>Lifetime suicide rates in treated schizophrenia: 1875–1924 and 1994–1998 cohorts compared</article-title>. <source>British Journal of Psychiatry</source> <volume>188</volume>, <fpage>223</fpage>–<lpage>228</lpage>.</citation></ref><ref><citation id="ref024" citation-type="journal"><name><surname>Heath</surname><given-names>I.</given-names></name> (<year>2006</year>). <article-title>Combating disease mongering: daunting but nonetheless essential</article-title>. <source>PLoS Medicine</source> <volume>3</volume>, e<fpage>146</fpage>.</citation></ref><ref><citation id="ref025" citation-type="journal"><name><surname>Joukamaa</surname><given-names>M.</given-names></name>, <name><surname>Heliövaara</surname><given-names>M.</given-names></name>, <name><surname>Knekt</surname><given-names>P.</given-names></name>, <name><surname>Aromaa</surname><given-names>A.</given-names></name>, <name><surname>Raitasalo</surname><given-names>R.</given-names></name> & <name><surname>Lehtinen</surname><given-names>V.</given-names></name> (<year>2006</year>). <article-title>Schizophrenia, neuroleptic medication and mortality</article-title>. <source>British Journal of Psychiatry</source> <volume>188</volume>, <fpage>122</fpage>–<lpage>127</lpage>.</citation></ref><ref><citation id="ref026" citation-type="book"><name><surname>Kassirer</surname><given-names>J.</given-names></name> (<year>2005</year>). <source>On the Take. How Medicine's Complicity with Big Business Can Endanger Your Health</source>. <publisher-name>Oxford University Press</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation></ref><ref><citation id="ref027" citation-type="journal"><name><surname>Keller</surname><given-names>M.D.</given-names></name>, <name><surname>Ryan</surname><given-names>N.D.</given-names></name>, <name><surname>Strober</surname><given-names>M.</given-names></name>, <name><surname>Klein</surname><given-names>R.G.</given-names></name>, <name><surname>Kutcher</surname><given-names>S.P.</given-names></name>, <name><surname>Birmaher</surname><given-names>B.</given-names></name>, <name><surname>Hagino</surname><given-names>O.R.</given-names></name>, <name><surname>Koplewicz</surname><given-names>H.</given-names></name>, <name><surname>Carlsson</surname><given-names>G.A.</given-names></name>, <name><surname>Clarke</surname><given-names>G.N.</given-names></name>, <name><surname>Emslie</surname><given-names>G.J.</given-names></name>, <name><surname>Feinberg</surname><given-names>D.</given-names></name>, <name><surname>Geller</surname><given-names>B.</given-names></name>, <name><surname>Kusumakar</surname><given-names>V.</given-names></name>, <name><surname>Papatheodorou</surname><given-names>G.</given-names></name>, <name><surname>Sack</surname><given-names>W.H.</given-names></name>, <name><surname>Sweeney</surname><given-names>M.</given-names></name>, <name><surname>Wagner</surname><given-names>K.D.</given-names></name>, <name><surname>E</surname><given-names>Weller</given-names></name>, <name><surname>Winters</surname><given-names>N.C.</given-names></name>, <name><surname>Oakes</surname><given-names>R.</given-names></name> & <name><surname>McCafferty</surname><given-names>J.P.</given-names></name> (<year>2001</year>). <article-title>Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial</article-title>. <source>Journal of American Academy of Child and Adolescent Psychiatry</source> <volume>40</volume>, <fpage>762</fpage>–<lpage>772</lpage>.</citation></ref><ref><citation id="ref028" citation-type="journal"><name><surname>Lemmens</surname><given-names>T.</given-names></name> & <name><surname>Freedman</surname><given-names>B.</given-names></name> (<year>2000</year>). <article-title>Ethics review for sale? Conflict of interest and commercial research review boards</article-title>. <source>Milbank Quarterly</source> <volume>78</volume>, <fpage>547</fpage>–<lpage>584</lpage>.</citation></ref><ref><citation id="ref029" citation-type="journal"><name><surname>Lieberman</surname><given-names>J.A.</given-names></name>, <name><surname>Stroop</surname><given-names>T.S.</given-names></name>, <name><surname>McEvoy</surname><given-names>J.P.</given-names></name>, <name><surname>Swartz</surname><given-names>M.S.</given-names></name>, <name><surname>Rosenheck</surname><given-names>R.A.</given-names></name>, <name><surname>Perkins</surname><given-names>D.O.</given-names></name>, <name><surname>Keefe</surname><given-names>R.S.</given-names></name>, <name><surname>Davis</surname><given-names>S.M.</given-names></name>, <name><surname>Davis</surname><given-names>C.E.</given-names></name>, <name><surname>Lebowitz</surname><given-names>B.D.</given-names></name>, <name><surname>Severe</surname><given-names>J.</given-names></name>, <name><surname>Hsiao</surname><given-names>J.</given-names></name>K & <article-title>Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia</article-title>. <source>New England Journal of Medicine</source> <volume>353</volume>, <fpage>1209</fpage>–<lpage>1223</lpage>.</citation></ref><ref><citation id="ref030" citation-type="book"><name><surname>Moynihan</surname><given-names>R.</given-names></name> & <name><surname>Cassels</surname><given-names>A.</given-names></name> (<year>2005</year>). <source>Selling Sickness</source>. <publisher-name>Nation Books</publisher-name>: <publisher-loc>New York</publisher-loc>.</citation></ref><ref><citation id="ref031" citation-type="book"><name><surname>Petryna</surname><given-names>A.</given-names></name> (<year>2006</year>). Globalizing human subjects research. In <source>Global Pharmaceuticals. Ethics, Markets, Practices</source> (ed. <name><surname>Petryna</surname><given-names>A.</given-names></name>, <name><surname>Lakoff</surname><given-names>A.</given-names></name> <name><surname>and</surname><given-names>A.</given-names></name> <name><surname>Kleinman</surname></name>), pp. <fpage>33</fpage>–<lpage>60</lpage>. <publisher-name>Duke University Press</publisher-name>: <publisher-loc>Durham</publisher-loc>.</citation></ref><ref><citation id="ref032" citation-type="book"><name><surname>Shepherd</surname><given-names>M.</given-names></name> (<year>1998</year>). Psychopharmacology: specific and non-specific. In <source>The Psychopharmacologists</source>, Vol. <volume>2</volume> (by <name><surname>Healy</surname><given-names>D.</given-names></name>), pp. <fpage>237</fpage>–<lpage>258</lpage>. <publisher-name>Arnold</publisher-name>: <publisher-loc>London</publisher-loc>.</citation></ref><ref><citation id="ref033" citation-type="book"><name><surname>Thompson</surname><given-names>J.</given-names></name>, <name><surname>Baird</surname><given-names>P.</given-names></name> & <name><surname>Downie</surname><given-names>J.</given-names></name> (<year>2001</year>). <source>The Olivieri Report</source>. <publisher-name>James Lorimer & Co.</publisher-name>: <publisher-loc>Toronto</publisher-loc>.</citation></ref><ref><citation id="ref034" citation-type="other"><collab>United States Patent</collab> (<year>1991</year>). No. 4,988,731. Date of Patent Jan 29<sup>th</sup>1991.</citation></ref><ref><citation id="ref035" citation-type="other"><collab>United States Patent</collab> (<year>1992</year>). No. 5,229,382. Date of Patent May 22, 1992. European patent, EP0,454,436, filed on April 24, 1991.</citation></ref><ref><citation id="ref036" citation-type="other"><collab>United States Patent</collab> (<year>1993</year>). No. 5,212,326. Date of Patent May 18<sup>th</sup> 1993.</citation></ref></ref-list></back></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>The engineers of human souls & academia</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>The engineers of human souls & academia</title></titleInfo><name type="personal"><namePart type="given">David</namePart><namePart type="family">Healy</namePart><affiliation>E-mail: Healy_Hergest@compuserve.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Cambridge University Press</publisher><place><placeTerm type="text">Cambridge, UK</placeTerm></place><dateIssued encoding="w3cdtf">2007-09</dateIssued><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract type="normal">Aims – There has been recent concern about interactions between academia and the pharmaceutical industry. This article seeks to explore the basis for the current sense of crisis. Methods – The approach taken is a historical one, outlining the origins of the crisis. Results – The analysis outlines the roles that brands, patents, and the control of the scientific literature play in the current marketing of psychotropic drugs, and describes the processes of guideline capture and brand fascism. Conclusions – The analysis makes it difficult to see current interactions between industry and academia as anything but bad for academia. One option that might restore some balance would be to restrict scientific meetings and journals to communications that made all relevant scientific data available, excluding exercises that restrict access to data. Declaration of Interest: In recent years I have had consultancies with, or been a chairman or speaker at symposia for, or received support to attend meetings from Astra-Zeneca, and Lundbeck. I have been expert witness for the plaintiff in the past decade in 15 legal actions involving antidepressants and on patent case, and have been consulted on a much greater number of attempted suicide, suicide, and suicide-homicide cases linked to treatment, in which I have offered the view that the treatment was not involved or have declined to give a view.</abstract><relatedItem type="host"><titleInfo><title>Epidemiologia e Psichiatria Sociale</title></titleInfo><titleInfo type="abbreviated"><title>Epidemiol Psichiatr Soc</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">1121-189X</identifier><identifier type="eISSN">2038-1816</identifier><identifier type="PublisherID">EPS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>16</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>205</start><end>211</end><total>7</total></extent></part></relatedItem><identifier type="istex">E9BF9DC0746E22F7668269B6A6EED6928D58131E</identifier><identifier type="ark">ark:/67375/6GQ-R442T4MV-M</identifier><identifier type="DOI">10.1017/S1121189X0000230X</identifier><identifier type="PII">S1121189X0000230X</identifier><identifier type="ArticleID">00230</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © Cambridge University Press 2007</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-G3RCRD03-V">cambridge</recordContentSource><recordOrigin>Copyright © Cambridge University Press 2007</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6GQ-R442T4MV-M/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/StressCovidV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000996 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000996 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= StressCovidV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E9BF9DC0746E22F7668269B6A6EED6928D58131E
|texte= The engineers of human souls & academia
}}
| This area was generated with Dilib version V0.6.33. |  |